Gene

MET

MET proto-oncogene, receptor tyrosine kinase

Explore in graph →CI-GENE-00012412HGNC:7029 ENSG00000105976 NCBI 4233 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (140)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 140 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Amplification + MET AmplificationEGFR MET1
(prognostic)	Malignant Gastric Neoplasm	Prognostic	B	Supports Poor Outcome

Cohorts

Alteration frequency by cohort (132)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved132 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (30)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 30 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
· Cell · 2015 · PMID 26359985 · validated civic_curation pubmed
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
· J Clin Oncol · 2013 · PMID 23213094 · validated

MET Amplification20
(prognostic)	Esophageal Carcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID11452 A total of 185 patients with stage III or IV esophageal + junctional cancers were tested for amplified genes in this retrospective study. There were 5 MET amplifications, 14 EGFR amplifications, and 1… (full text at CIViC) PMID 22042947 · Lennerz et al., 2011 · Open in CIViC	civic
Cabozantinib	Gastric Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID7873 Cabozantinib's effect on cell proliferation was studied in a variety of cell lines. In two gastric adenocarcinoma cell lines with MET amplification (SNU-5 and Hs746T) were the most sensitive to caboz… (full text at CIViC) PMID 21926191 · Yakes et al., 2011 · Open in CIViC	civic
Capmatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID8849 In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations received the MET inhibitor Capmatinib after assignment to cohorts based on prior treatment and type of M… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC	civic
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7502 In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC) PMID 31416808 · Landi et al., 2019 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7639 Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib. MET amplification was defined as more than or equal to 6 copies. The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC	civic
〃	Malignant Digestive System NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	submitted	EID11454 Four patients with MET amplified gastroesophageal cancer (GEC) were treated with crizotinib (250 mg, twice daily). Two patients showed rapid progression, showing growth only 43 and 27 days respectivel… (full text at CIViC) PMID 22042947 · Lennerz et al., 2011 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID735 A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib. PMID 21623265 · Ou et al., 2011 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID1565 A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizoti… (full text at CIViC) PMID 22162573 · Chi et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1692 In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP. The patient attained a reduction in the target lesions by 38.7%, and the pa… (full text at CIViC) PMID 25922291 · Le et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1714 Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treat… (full text at CIViC) PMID 25232318 · Palma et al., 2014 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11383 A 72-year old woman (former smoker: 12 pack-years) with advanced lung adenocarcinoma received 250 mg of crizotinib twice daily after first line chemotherapy with carboplatin, pemetrexed, and maintenan… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID836 Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib. PMID 26724472 · Zhang et al., 2016 · Open in CIViC	civic
〃	Lung Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID890 Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was… (full text at CIViC) PMID 24192513 · Schwab et al., 2014 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1713 Case report of two patients with MET amplification (MET:CEP7 ratio ≥5) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification ma… (full text at CIViC) PMID 27664533 · Caparica et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID1566 2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had… (full text at CIViC) PMID 21716144 · Tanizaki et al., 2011 · Open in CIViC	civic
Crizotinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID1588 Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy… (full text at CIViC) PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	4	accepted	EID733 In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET. Resistance was conferred by the MET amplification driving ERBB3 (HER… (full text at CIViC) PMID 17463250 · Engelman et al., 2007 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID1392 155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to E… (full text at CIViC) PMID 23470965 · Yu et al., 2013 · Open in CIViC	civic
Onartuzumab	Gastric Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID689 A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response … (full text at CIViC) PMID 22389872 · Catenacci et al., 2011 · Open in CIViC	civic
Savolitinib	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID7729 In a multi-cohort biomarker selected phase 2 study, patients with gastric cancer harboring MET amplification were treated with Savolitinib. Gene alterations were evaluated using tumor samples. MET amp… (full text at CIViC) PMID 31315834 · Lee et al., 2019 · Open in CIViC	civic

MET Amplification + MET Exon 14 Skipping Mutation4
Crizotinib	Lung Sarcomatoid Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11375 A 74-year-old woman with stage II Pulmonary Sarcomatoid Carcinoma (PSC) was treated with neoadjuvant platinum/taxane chemotherapy with no improvement. Chemotherapy was stopped due to resistance and po… (full text at CIViC) PMID 26215952 · Liu et al., 2016 · Open in CIViC	civic
(prognostic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	submitted	EID11387 A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation or MET amplification. Univariable analysis showed that shorter overall disease-specific survival was … (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC	civic
(diagnostic)	Lung Sarcomatoid Carcinoma	Diagnostic	B	Supports Positive	5	submitted	EID11388 A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation. In 18 cases with MET exon 14 skipping mutations, 2.6% had adenocarcinoma, 4.8% had adenosquamous cel… (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC	civic
Capmatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	submitted	EID11458 Twenty patients with advanced non-small-cell lung cancer (NSCLC) with MET amplification or MET exon 14 skipping mutations were enrolled in this phase II clinical trial. All patients first received cri… (full text at CIViC) PMID 33545388 · Dagogo-Jack et al., 2021 · Open in CIViC	civic

MET Amplification + MYC AmplificationMET MYC2
Capmatinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	3	submitted	EID11420 An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC) PMID 36248327 · Choi et al., 2022 · Open in CIViC	civic
Capmatinib + ICX-101Sequential	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11421 A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC) PMID 36248327 · Choi et al., 2022 · Open in CIViC	civic

KRAS Mutation + MET AmplificationMET KRAS2
Cetuximab + CrizotinibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1979 Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated wi… (full text at CIViC) PMID 23729478 · Bardelli et al., 2013 · Open in CIViC	civic
Cetuximab/Irinotecan Regimen + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID1971 7 patients with acquired resistance to EGFR inhibitors were analyzed in this study. Of these, 4 did not develop KRAS mutations. Post- and Pre-Treatment tissued was available of three patients and MET … (full text at CIViC) PMID 23729478 · Bardelli et al., 2013 · Open in CIViC	civic

MET D1010H2
Crizotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4792 In a lung adenocarcinoma patient harboring MET D1028H mutation, a partial response to crizotinib treatment was reported with continued response for at least 6 months. Prior to crizotinib treatment, th… (full text at CIViC) PMID 25898962 · Waqar et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4793 In a lung adenocarcinoma patient harboring a MET D1010H mutation, stable disease to crizotinib monotherapy was reported. The patient was treated with crizotinib for 4 months; treatment was ongoing at … (full text at CIViC) PMID 27343443 · Schrock et al., 2016 · Open in CIViC	civic